目的 探讨曲安奈德注射液联合巴曲酶注射液治疗突发性耳聋的临床疗效。方法 选取2016年3月-2017年3月南阳市中心医院耳鼻喉科收治的突发性耳聋患者125例为研究对象，所有患者在随机分组的原则下分为对照组（62例）和治疗组（63例）。对照组均静脉滴注巴曲酶注射液，首次10 BU（而后5 BU）加入到生理盐水250 mL中，1次/2 d。治疗组患者在对照组基础上鼓室内注射曲安奈德注射液，40 mg/次，1次/2 d。两组患者均连续治疗10 d。观察两组的临床疗效，比较两组的临床症状、平均听阈提高值、纤维蛋白原（FIB）、缝隙连接蛋白原26（connexin 26）、缝隙连接蛋白原30（connexin 30）水平。结果 治疗后，对照组和治疗组的总有效率分别为83.87%、96.83%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组听力恢复时间、耳鸣消失时间、眩晕消失时间明显短于对照组，且治疗组平均听阈提高值明显高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组FIB水平显著降低，connexin 26、connexin 30水平显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 曲安奈德注射液联合巴曲酶注射液治疗突发性耳聋具有较好的临床疗效，可改善临床症状，升高平均听阈值，调节FIB、connexin 26、connexin 30水平，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Triamcinolone Acetonide Injection combined with Batroxobin Injection in treatment of sudden deafness. Methods Patients (125 cases) with sudden deafness in Department of Ear-Nose-Throat of Nangyang City Central Hospital from March 2016 to March 2017 were randomly divided into the control group (62 cases) and the treatment group (63 cases). Patients in the control group were iv administered with Batroxobin Injection, first dosage 10 BU (then 5 BU) added into normal saline 250 mL, once every two days. Patients in the treatment group were intratincular injection administered with Triamcinolone Acetonide Injection on the basis of the control group, 40 mg/time, once every two days. Patients in two groups were treated for 10 d. After treatment, the clinical efficacies were evaluated, and clinical symptoms, average hearing threshold increased value, and the levels of FIB, connexin 26, and connexin 30 in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 83.87% and 96.83%, respectively, and there was difference between two groups (P < 0.05). After treatment, hearing recovery time, tinnitus disappearance time, and vertigo disappearance time in the treatment group were shorter than those in the control group, and the average hearing threshold increased values in the treatment group was higher than those in the control group, and there was difference between two groups (P < 0.05). After treatment, the levels of FIB in two groups were significantly decreased, but the levels of connexin 26 and connexin 30 in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Triamcinolone Acetonide Injection combined with Batroxobin Injection has clinical curative effect in treatment of sudden deafness, can improve clinical symptom, increase average hearing threshold, and regulate the levels of FIB, connexin 26, and connexin 30, which has a certain clinical application value.